Overview

Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia

Status:
Withdrawn

Trial end date:
2017-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of NK-104-CR with Placebo and Livalo® on the reduction of LDL-C and to evaluate the safety of NK-104-CR in patients with primary hyperlipidemia or mixed dyslipidemia

Phase:

Phase 3

Details

Lead Sponsor:

Kowa Research Institute, Inc.

Treatments:

Pitavastatin